Search clinical trials for: Mirabegron 50 MG [Myrbetriq]

Total 832 results

Cedars-Sinai Medical Center

Recruiting

Using Mirabegron to Increase BP in Patients With POTS (RAISE BP)

Syncope | Postural Orthostatic Tachycardia Syndrome | Chronic Orthostatic Intolerance

United States
Thomas Jefferson University
Astellas Pharma Inc

Terminated

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

Achalasia

United States
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
University Hospitals Cleveland Medical Center

Withdrawn

Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder

Overactive Bladder

United States
Shachi Tyagi
National Institute on Aging (NIA)

Recruiting

Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women (SLAB)

Nocturia | Urgency Urinary Incontinence

United States
Walter Reed National Military Medical Center

Recruiting

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

Overactive Bladder Syndrome

United States
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Overactive Bladder | Neurogenic Detrusor Overactivity

Denmark, Poland
Unity Health Toronto
Canadian Urological Association

Unknown

Mirabegron And Ureteral Stent-related Pain (MAP) Trial (MAP)

Nephrolithiasis

Canada
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Healthy

Egypt
Seoul National University Hospital
Il-Yang Pharm. Co., Ltd.

Not yet recruiting

A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Overactive Bladder

Korea, Republic of
The Affiliated Ganzhou Hospital of Nanchang University

Active, not recruiting

Acupuncture Combined With Mirabegron in the Treatment of OAB (ACWMITTOOAB)

Overactive Bladder

China
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Brown Fat Activation Study

Metabolic Syndrome | Obese

United States
Chang Gung Memorial Hospital

Completed

Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms

Urinary Bladder, Overactive | Sexual Behavior | Sexual Function Disturbances | Behavior Therapy | Sexual Activity

Taiwan
Genuine Research Center, Egypt
Multi-Apex Pharma

Completed

Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)

Healthy

Egypt
CHU de Quebec-Universite Laval

Completed

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder (Mirabegron)

Overactive Bladder | Urinary Incontinence
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and Symptoms

Belarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
HealthPartners Institute

Completed

Mirabegron in Parkinson Disease and Impaired Cognition (MICT-PD)

Overactive Bladder | Parkinson Disease | Impaired Cognition

United States
University of Alabama at Birmingham

Completed

Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study) (PTNS-M)

Overactive Bladder

United States
Zydus Lifesciences Limited

Recruiting

Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

India
Chang Gung Memorial Hospital

Unknown

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Overactive Bladder Syndrome | Detrusor Overactivity
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

Philippines, Turkey, Belgium, Denmark
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Obesity | Pre-diabetes

United States
Hasanuddin University

Completed

COMPARISON OF THE EFFECTS OF MIRABEGRON AND TAMSULOSIN

Kidney Stones | Ureteral Stone | Ureteral Stenosis

Indonesia
Alcon Research

Completed

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration
Sprout Pharmaceuticals, Inc

Completed

Flibanserin Versus Placebo in Premenopausal Women With HSDD

Sexual Dysfunctions, Psychological

Austria, Belgium, Czech Republic, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom
Eisai Korea Inc.

Recruiting

A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)

Parkinson Disease

Korea, Republic of
Serdinsek Tamara

Completed

Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder

Overactive Bladder | Overactive Bladder Syndrome

Slovenia
Kasr El Aini Hospital

Unknown

Impact of Mirabegron on Erectile Function in BPH Patients

Males With Benign Prostatic Hyperplasia Symptoms
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178

Metabolic Processes

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany, Australia, Canada, Denmark, Italy, Poland, Serbia, Spain, Switzerland
CymaBay Therapeutics, Inc.

Completed

Study to Evaluate the Effects of MBX-8025 in Patients With HoFH

Homozygous Familial Hypercholesterolemia

Canada, France, Netherlands, Norway
Tourmaline Bio, Inc.

Recruiting

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 75 Years of Age With Thyroid Eye Disease (spiriTED)

Thyroid Eye Disease

United States, Jordan
Aaron Cypess
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Completed

Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue

Obesity

United States
GlaxoSmithKline

Completed

Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance

Gastroparesis

Australia
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions

Healthy Subjects | Pharmacokinetics of YM178

Netherlands
Pfizer

Completed

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Healthy Volunteer

Netherlands
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy (CLMF237A1303)

Diabetes Mellitus, Type 2

Japan
Sagimet Biosciences Inc.

Completed

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Cirrhosis | Hepatic Impairment | Non-alcoholic Steatohepatitis

United States, Hungary
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
Pfizer

Completed

A Target Occupancy Study With Ritlecitinib.

Healthy

United States
Repros Therapeutics Inc.

Terminated

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Uterine Fibroids

United States
Vigonvita Life Sciences

Completed

Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Healthy Subjects

China
Novo Nordisk A/S

Completed

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity (OASIS 2)

Overweight and Obesity

Japan, Korea, Republic of
Zambon SpA

Completed

A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers

Healthy

China
CHU de Quebec-Universite Laval

Completed

Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder (Add-on-Mira)

Overactive Bladder | Urinary Incontinence
Idorsia Pharmaceuticals Ltd.

Completed

Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Insomnia Disorder

United States, Germany, Canada, Denmark, Poland, Spain, Switzerland, Belgium, Bulgaria, Finland, France, Hungary, Korea, Republic of, Sweden
The HIV Netherlands Australia Thailand Research...
Radboud University Medical Center; Bhumibol Adulyadej Hospital; Klang Hospital; Bamrasnaradura Infectious Diseases Institute and other collaborators

Recruiting

Efficacy, Safety and Pharmacokinetics of DTG With RIF

HIV/TB Coinfection

Thailand
Ardelyx

Recruiting

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented

Healthy

Netherlands

Search clinical trials for: Mirabegron 50 MG [Myrbetriq]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations